Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer
15 sept. 2020 07h00 HE
|
Aravive, Inc.
HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry...
Aravive to Participate in Upcoming Virtual Investor Conferences in September
08 sept. 2020 07h00 HE
|
Aravive, Inc.
HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and...
Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans
27 août 2020 07h00 HE
|
Aravive, Inc.
HOUSTON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced the appointment of three...
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
03 août 2020 16h01 HE
|
Aravive, Inc.
Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with...
Aravive to Participate in Upcoming Virtual Investor Conferences in August
30 juil. 2020 07h00 HE
|
Aravive, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and...
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer
23 juil. 2020 07h00 HE
|
Aravive, Inc.
Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500 in Platinum Resistant Ovarian Cancer Aravive to Host Conference Call and Webcast Today at 8:30 a.m. ET HOUSTON, July...
Aravive Added to the Russell 2000® and Russell 3000® Indexes
30 juin 2020 16h05 HE
|
Aravive, Inc.
HOUSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference
12 mai 2020 08h00 HE
|
Aravive, Inc.
HOUSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates
06 mai 2020 16h05 HE
|
Aravive, Inc.
HOUSTON, May 06, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
30 avr. 2020 08h00 HE
|
Aravive, Inc.
HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with...